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A series of N-substituted 2-{[5-(1H-indol-3-ylmethyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetamides (8a-w) 
was synthesized in three steps. The first step involved the sequential conversion of 2-(1H-indol-3-yl)
acetic acid (1) to ester (2) followed by hydrazide (3) formation and finally cyclization in the presence 
of CS
2 and alcoholic KOH yielded 5-(1H-indole-3-yl-methyl)-1,3,4-oxadiazole-2-thiol (4). In the second 
step, aryl/aralkyl amines (5a-w) were reacted with 2-bromoacetyl bromide (6) in basic medium to yield 
2-bromo-N-substituted acetamides (7a-w). In the third step, these electrophiles (7a-w) were reacted with 
4 to afford the target compounds (8a-w). Structural elucidation of all the synthesized derivatives was 
done by 1H-NMR, IR and EI-MS spectral techniques. Moreover, they were screened for antibacterial 
and hemolytic activity. Enzyme inhibition activity was well supported by molecular docking results, for 
example, compound 8q exhibited better inhibitory potential against α-glucosidase, while 8g and 8b 
exhibited comparatively better inhibition against butyrylcholinesterase and lipoxygenase, respectively. 
Similarly, compounds 8b and 8c showed very good antibacterial activity against Salmonella typhi, 
which was very close to that of ciprofloxacin, a standard antibiotic used in this study. 8c and 8l 
also showed very good antibacterial activity against Staphylococcus aureus as well. Almost all 
compounds showed very slight hemolytic activity, where 8p exhibited the least. Therefore, the 
molecules synthesized may have utility as suitable therapeutic agents. 
Uniterms: 1H-indol-3-acetic acid.  N-substituted 2-{[5-(1H-indol-3-ylmethyl)-1,3,4-oxadiazol-2-yl] 
sulfanyl}acetamides/antibacterial activity. N-substituted 2-{[5-(1H-indol-3-ylmethyl)-1,3,4-oxadiazol- 
2-yl]sulfanyl} acetmides/hmolytic activity. α-Glicosidase. Butirylcholinesterase. Lipoxygenase. 
Uma série de acetamidas 2-{[5-(1H-indol-3-ilmetil)-1,3,4-oxadiazol-2-il]sulfanila} N-substituídas (8a-w) 
foi sintetizada em três fases. A primeira etapa envolveu a conversão sequencial de ácido 2-(1H-indol-3-il)
acético (1) a éster (2), seguido por hidrazida (3) e, finalmente, a e ciclização na presença de CS2 e KOH 
alcoólico produziu 5-(1H-indol-3-il- metil)-1,3,4-oxadiazole-2-tiol (4). Na segunda etapa, aminas arílicas/
aralquílicas(5a-w) reagiram com brometo de 2-bromoacetila (6 ), em meio básico, para se obter acetamidas 
2-bromo-N-substituídas (7a-w). Na terceira etapa, estes eletrófilos (7a- w) reagiram com 4, para se obter 
os compostos alvo (8a-w). A elucidação estrutural de todos os derivados sintetizados foi realizada por 
1H-NMR, IR e técnicas de espectrometria de EI-MS. Além disso, eles foram submetidos a triagem de 
atividade antibacteriana e hemolítica. Análise da inibição enzimática foi bem apoiada pelos resultados de 
docking molecular. Por exemplo, o composto 8q exibiu melhor potencial inibitório contra α-glicosidase, 
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e os compostos 8g e 8b exibiram, comparativamente, melhor inibição contra butirilcolinesterase (BChE) 
elipoxigenase (LOX), respectivamente. Do mesmo modo os compostos 8b e 8c mostraram excelente 
potencial antibacteriano contra SalmonellaTyphi, semelhante ao do ciprofloxacino, antibiótico padrão 
usado neste estudo. Os compostos 8c e 8l também mostraram excelente potencial antibacteriano contra 
Staphylococcus aureus . Quase todos os compostos mostraram pequena atividade hemolítica, sendo que 
o composto 8p apresentou menor atividade. Assim, as moléculas sintetizadas podem ter a sua utilidade 
como agentes terapêuticos adequados.
Unitermos: Ácido 1H-indol-3-acético. Acetamidas 2-{[5-(1H-indol-3-ilmetil)-1,3,4-oxadiazol-2-il]
sulfanila}N-substituídas/atividade antibacteriana. Acetamidas 2-{[5-(1H-indol-3-ilmetil)-1,3,4-oxadiazol-
2-il]sulfanila}N-substituídas/atividade hemolítica. α-Glicosidase. Butirilcolinesterase. Lipoxigenase.
INTRODUCTION
Oxadiazoles comprise four different classes, 
where 1,3,4-oxadiazoles are more important and are 
present in a number of biologically active molecules. 
(Renukadevi, Birada, 1999). Due to the propensity of the 
1,3,4-oxadiazole ring to undergo a variety of electrophilic 
and nucleophilic substitution reactions, a large number of 
derivatives have been synthesized that have remarkable 
pharmacological, medicinal, and biological activities 
such as antimicrobial (Rakesh et al., 2010; Zuhair et al., 
2008), anti-inflammatory (Dewangan et al., 2010; Omar, 
Mahfouz, Rahman, 1996), cytotoxic and hypoglycemic 
(Hasan et al., 2011), anticancer (Bhatnacar et al., 1986), 
anticonvulsive (Yar, Akhter, 2009), antitubercular (Ali, 
Shaharyar, 2007), and fungicidal and insecticidal (Zou, 
Zhang, Jin, 2002; Holla et al., 2004). Indole derivatives 
display a wide range of biological activities. The indole 
ring is found in the hormones serotonin and melatonin, 
amino acid tryptophan, the anti- inflammatory drug 
indomethacin, the psychotropic drug LSD and the 
antitumor agents vinblastine and vincristine (Murphy 
et al., 1997). Coronaridine and voacangine are indole 
alkaloids that have antileishmanial, antitumor, diuretic 
and hypoglycemic activities (Camila, Paulo, Meireles, 
2007). The indole moiety has been incorporated as a 
core skeleton to access active sites, implicated in enzyme 
inhibitions (Lednicer, 2007). Some indole derivatives are 
also identified as good inhibitors of 5- lipoxygenase (LOX) 
(Hutchinson et al., 1995; Yar et al., 2014). LOX is a lipid-
peroxidizing enzyme, which shows an essential role in 
leukotriene biosynthesis and mediates the pathophysiology 
of allergic disorders, inflammatory reactions and neo-
angiogenesis (Bhattacharjee, 2005; Jampilek et al., 
2006; Pommery et al., 2004). Cholinesterases are well-
known enzymes that are present in cholinergic and non-
cholinergic tissues and in plasma and other body fluids of 
animals (Ryhanen, 1983). Butrylcholinesterase (BChE) 
is present in intestine, liver, heart, kidneys and lungs 
(Dave et al., 2000). BChE hydrolyzes ester-containing 
drugs and scavenges cholinesterase inhibitors, including 
potent organophosphorus nerve agents before reaching the 
synaptic targets (Silver, 1974). Inhibitors of the enzyme 
α-glucosidase are molecules that are used as oral anti-
diabetic drugs in the treatment of type-2 diabetes mellitus. 
The inhibitors of this enzyme can delay the release of 
D-glucose from disaccharides and oligosaccharides from 
dietary carbohydrates and slow down glucose absorption, 
resulting in reduced postprandial hyperglycemia (Lebovitz, 
1997). Therefore, inhibition of α-glucosidase is considered 
important in managing type-2 diabetes. Cytotoxicity of 
synthesized compounds in terms of hemolytic activity 
may be studied to assess the possible toxicity profile of the 
most active compounds. Shirinzadeh et al. (2010) studied 
indole hydrazide/hydrazone derivatives for their inhibitory 
effect on AAPH–induced hemolysis of human erythrocytes 
and found most of the compounds had significantly high 
antioxidant activity, when compared to melatonin. A new 
series of 2-[[5-alkyl/aralkyl-1,3,4-oxadiazol-2-yl]thio]-
N-[4-(4-morpholinyl)phenyl]acetamides was evaluated 
by Akhtar et al. (2014) for antimicrobial and hemolytic 
activity; most of them were found to be active against the 
selected microbial species to a variable extent relative to 
reference standards, and showed less toxicity as well.
The aim of present study was to design and 
synthesize some novel poly-functional compounds having 
1,3,4-oxadiaozole, indole and substituted acetamide 
moieties together in one molecule, which may prove to be 
potent antibacterial and anti-enzymatic agents and which 
could be studied further for pharmacological purposes.
MATERIAL AND METHODS
General
The chemicals employed in this study were of 
analytical grade and purchased from Merck and Alfa 
Aesar. All solvents were distilled before use. Melting 
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points of the synthesized compounds were recorded on 
a Gallenkamp melting point apparatus by open capillary 
tube and were uncorrected. To observe the progress of the 
reaction, thin layer chromatography (TLC) was carried 
out on pre-coated silica gel G-25-UV254 plates using ethyl 
acetate and n-hexane in various proportions as mobile 
phase. Spots were visualized at 254 nm under a UV lamp. 
IR spectra were recorded using the KBr pellet method with 
a HYPER IR spectrometer, and wave number was given in 
cm-1. Mass spectra (EI-MS) were recorded using a JOEL 
JMS 600H spectrometer, with a data system. Nuclear 
magnetic resonance spectra were recorded in DMSO-d6 
on a Bruker spectrometer operating at 300-500 MHz, and 
chemical shifts (δ) were given in ppm.
Synthesis
Preparation of ethyl 2-(1H-indol-3-yl)acetate (2)
2-(1H-Indol-3-yl)acetic acid (20.0 g; 0.11 mol; 
1) in absolute ethanol (60 mL) and catalytic amount 
of concentrated sulfuric acid (10 mL; 0.18 mol) were 
added to a 500-mL round-bottomed flask (RB), which 
was refluxed for 8 h until completion of the reaction. The 
reaction mixture was neutralized with 20 mL of 10% 
aqueous sodium carbonate. The product was isolated by 
the solvent extraction technique using chloroform (50x3 
mL). The organic phase containing the ester was decanted 
off and washed a number of times with distilled water and 
dried using anhydrous MgSO4.
Preparation of 2-(1H-indol-3-yl)acetohydrazide (3)
Ethyl 2-(1H-indol-3-yl)acetate (19.0 mL; 2) in 30 
mL of methanol and hydrazine hydrate (80%; 25 mL) 
was added to a 500-mL RB flask. The reaction mixture 
was stirred for 3 h at room temperature. After absolute 
conversion, the acid hydrazide was obtained by distilling 
methanol from the reaction mixture. The precipitates were 
filtered, washed with n-hexane and air-dried to yield pure 
2-(1H-indol-3-yl)acetohydrazide (3).
Preparation of 5-(1H-indole-3-yl-methyl)-1,3,4-
oxadiazole-2-thiol (4)
2-(1H-Indol-3-yl)acetohydrazide (20.0 g, 0.11 mol; 
3) in absolute ethanol (30 mL) was added to a 500-mL RB 
flask. Potassium hydroxide (6.3 g, 0.11 mol) was added to 
the solution followed by the addition of carbon disulfide 
(14.0 mL; 0.22 mol) and the mixture refluxed with stirring 
for 6 h. Progress of the reaction was monitored by TLC, 
and on completion, it was diluted with distilled water (50 
mL) and acidified with dilute hydrochloric acid to pH 
5-6. The precipitates formed were filtered, washed with 
water and re-crystallized from ethanol to obtain pure 
5-(1H-indole-3-yl-methyl)-1,3,4-oxadiazole-2-thiol (4) 
in good yield.
Preparation of N-substituted 2-bromoacetamide 
electrophiles (7a-w)
Preparation of N-substituted 2-bromoacetamide 
derivatives was carried out by reaction of various aryl/
aralkyl amines (5a-w) with 2-bromoacetyl bromide (6) 
in equimolar quantities (0.001m) and shaking manually 
in 10% aqueous Na2CO3. Solid precipitates were formed 
after 10-20 min, filtered and washed with cold distilled 
water to obtain the desired electrophiles (7a-w).
Preparation of N-substituted 2-{[5-(1H-indol-3-
ylmethyl)-1,3,4-oxadiazol-2-yl]sulfanyl} acetamides 
(8a-w)
Equimolar quantities of 5-(1H-indol-3-yl-methyl)-
1,3,4-oxadiazole-2-thiol (0.001 mol; 4) and 2-bromo-N-
substituted acetamides (7a-w); in N-N-dimethylformamide 
(7 mL) and NaH (0.002 mol) were reacted in a 25-mL 
RB flask. The reaction mixture was stirred for 8 h at 35 
oC. After absolute conversion, the reaction mixture was 
poured on crushed ice; precipitates thus formed were 
filtered, washed with distilled water and dried to afford 
pure N-substituted 2-{[5-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazol-2-yl]sulfanyl}acetamides (8a-w) in good yields. 
The synthetic pathway is illustrated in Figure 1 and Table I 
(Sabahat et al., 2013).
Spectral characterization
Ethyl 1H-indole-3-acetate (2)
Brownish liquid; Yield: 79%; Molecular formula: 
C12H13N2O; Molecular Weight: 203 g/mol; IR (KBr) υmax: 
3415 (N-H), 3037 (C-H Ar), 1633 (C=O), 1534 (Ar C=C); 
1H-NMR (400 MHz): δ 10.9 (s, 1H, NH-1ʹ), 7.48 ( br.d, 
J = 8.0 Hz, 1H, H-4’), 7.34 (br.d, J = 8.0 Hz, 1H, H-7’), 
7.23 (br.s, 1H, H-2’), 7.06 (t, J = 7.6 Hz, 1H, H-5’), 6.97 
(t, J = 7.6 Hz, 1H, H-6’), 4.16 (q, J= 7.2, 2H, -OCH2CH3), 
3.71 (s, 2H, CH2-10ʹ), 1.17 (t, J = 7.2 Hz, 3H, -OCH2CH3); 
EIMS: m/z 203 (C12H13N2O)˙+ [M]+, 158 (C10H8NO)+, 130 
(C9H8N)+, 59 (C3H5O2)+.
2-(1H-Indol-3-yl)acetohydrazide (3)
Brownish crystals; Yield: 89%; m.p. 113 °C; 
Molecular formula: C10H11N3O; Molecular Weight: 189 
g/mol; IR (KBr) υmax: 3431 (N-H), 3032 (C-H Ar), 1630 
(C=O), 1529 (Ar C=C); 1H-NMR (400 MHz): δ 10.8 (s, 
1H, NH-1ʹ), 9.08 (s, 1H, NHNH2), 7.55 ( br.d, J = 7.6 Hz, 
1H, H-4’), 7.31 (br.d, J = 8.0 Hz, 1H, H-7’), 7.16 (br.s, 1H, 
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H-2’), 7.04 (t, J = 7.2 Hz, 1H, H-5’), 6.95 (t, J = 7.6 Hz, 
1H, H-6’), 4.16 ( br.s,1H, NHNH2) 3.43 (s, 2H, CH2-10ʹ); 
EIMS: m/z 189 (C10H11N3O)˙+ [M]+, 158 (C10H8NO)+, 130 
(C9H8N)+, 59 (C3H5O2)+.
2-(1H-Indol-3-yl-methyl)-1,3,4-oxadiazole-5-thiol (4)
Dark brown powder; Yield: 76%; m.p. 125 °C; 
Molecular formula: C11H9N3OS; Molecular Weight: 231 
gmol-1; IR (KBr) υmax: 3337 (N-H, stretching), 3085 (C-
H, str. of aromatic ring), 1562 (C=C, aromatic str.), 1666 
(C=N, str. of oxadiazole ring), 1065 (C-O-C bond str.), 
638 (C-S bond str.); 1H-NMR (400 MHz): δ 11.0 (s, 1H, 
NH-1ʹ), 7.49 ( br.d, J = 7.6 Hz, 1H, H-4’), 7.37 (br.d, J = 
8.0 Hz, 1H, H-7’), 7.34 (br.s, 1H, H-2’), 7.09 (t, J = 7.6 
Hz, 1H, H-5’), 7.00 (t, J = 7.6 Hz, 1H, H-6’), 4.20 (s, 2H, 
CH2-10ʹ). EIMS: m/z 233 (C11H9N3OS+2)˙+ [M+2]+, 231 
(C11H9N3OS)˙+ [M]+, 158 (C10H8NO)+, 156 (C10H8N2)+, 
130 (C9H8N)+.
N-Cyclohexyl-2-{[5-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazol-2-yl]sulfanyl}acetamide (8a)
Light brown amorphous; Yield: 83%; m.p. 139 °C; 
Molecular formula C19H22N4O2S; Molecular weight: 370 g/
mol; IR (KBr) υmax: 3341 (N-H, stretching), 3083 (C-H, str. 
of aromatic ring), 1658 (C=O str.), 1558 (C=C, aromatic 
str.), 1667 (C=N, str. of oxadiazole ring), 1065 (C-O-C 
bond str.), 638 (C-S bond str.); 1H-NMR (300 MHz): δ 
11.04 (s, 1H, NH-1’), 8.11 (d, J = 10.8 Hz, 1H, NH-1’’’’), 
7.48 (d, J = 8.1 Hz, 1H, H-4’), 7.35 (br. d, J = 8.1 Hz, 
1H, H-7’), 7.30 ( br. s, 1H, H-2’), 7.08 ( t, J = 6.9 Hz, 1H, 
H-5’), 6.98 ( t, J = 6.9 Hz, 1H, H-6’), 4.30 (s, 1H, H-10’) 
3.94 (s, 2H, H-2’’), 3.02 ( br.s, 1H, H-1’’’), 1.16-1.09 (m, 
10H, H-2’’’ to H-6’’’); EIMS: m/z 372 (C19H22N4O2S+2)˙+ 
[M+2]+, 370 (C19H21N4O2S)˙+ [M]+, 242 (C10H14N3O2S+2)+, 
233 (C11H9N3OS+2)+, 231 (C11H9N3OS)+, 158 (C10H8NO)+, 
156 (C10H8N2)+, 140 (C8H14NO)+, 130 (C9H8N)+, 126 
(C7H12NO)+, 98 (C7H12N)+, 83 (C6H11)+.
N-Phenyl-2-{[5-(1H-indol-3-ylmethyl)-1,3,4-oxadiazol-
2-yl]sulfanyl}acetamide (8b)
Brown amorphous powder; Yield: 80%; m.p. 153 
°C; Molecular formula: C19H16N4O2S; Molecular weight: 
364 g/mol IR (KBr) υmax: 3339 (N-H, stretching), 3086 
(C-H, str. of aromatic ring), 1654 (C=O str.), 1559 (C=C, 
aromatic str.), 1669 (C=N, str. of oxadiazole ring), 1067 
(C-O-C bond str.), 638 (C-S bond str.); 1H-NMR (400 
MHz): δ 11.03 (s, 1H, NH-1’), 8.77 ( s,1H, NH-1’’’’), 
7.54 (br.d, J = 8.0 Hz, 2H, H-2’’’ & H-6’’’), 7.49 (d, J = 
8.0 Hz, 1H, H-4’), 7.34 (br.d, J = 8.0 Hz, 1H, H-7’), 7.32 
( br.s, 1H, H-2’), 7.31-7.23 (m, 3H, H-3’’’ to H-5’’’), 7.07 
( t, J = 7.6 Hz, 1H, H-5’), 6.98 ( t, J = 6.8 Hz, 1H, H-6’), 
4.30 (s, 1H, H-10’), 4.26 ( br.s, 1H, H-2’’); EIMS: m/z 366 
FIGURE 1 - Outline for synthesis of N-substituted 2-{[5-(1H-indol-3-ylmethyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetamides (8a-w).
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(C19H16N4O2S)˙+ [M+2]+, 364 (C19H16N4O2S)˙+ [M]+, 362 
(C10H8N3O2S)+, 233 (C11H9N3OS+2)+, 231 (C11H9N3OS)+, 
158 (C10H8NO)+, 156 (C10H8N2)+, 134 (C8H8NO)+, 130 
(C9H8N)+, 120 (C8H10N)+, 92 (C6H6N)+, 77 (C6H5)+.
N-Benzyl-2-{[5-(1H-indol-3-ylmethyl)-1,3,4-oxadiazol-
2-yl]sulfanyl}acetamide (8c)
Light brown amorphous powder; Yield: 90%; m.p. 
148 °C; Molecular formula: C20H18N4O2S; Molecular 
weight: 378 g/mol; IR (KBr) υmax: 3343 (N-H, stretching), 
3088 (C-H, str. of aromatic ring), 1657 (C=O str.), 1560 
(C=C, aromatic str.), 1669 (C=N, str. of oxadiazole ring), 
1065 (C-O-C bond str.), 637 (C-S bond str.); 1H-NMR 
(400 MHz): δ 11.03 (s, 1H, NH-1’), 8.74 (t, J = 5.6 Hz, 
1H, NH-1’’’’), 7.49 (d, J = 8.0 Hz, 1H, H-4’), 7.36 (br.d, 
J = 8.0 Hz, 1H, H-7’ ), 7.30 ( br.s, 1H, H-2’), 7.28-7.26 
(m, 2H, H-2’’’ & H-6’’’), 7.23-7.20 (m, 3H, H-3’’’, H-4’’’ 
& H-5’’’), 7.08 ( t, J = 7.6 Hz, 1H, H-5’), 6.97 ( t, J = 6.9 
Hz, 1H, H-6’), 4.30 (s, 1H, H-10’), 4.26 ( br.s, 1H, H-2’’), 
4.05 ( br.s, 2H, H-7’’’); EIMS: m/z 380 (C20H18N4O2S+2)˙+ 
[M+2]+, 378 (C20H18N4O2S)˙+ [M]+, 233 (C11H9N3OS+2)+, 
231 (C11H9N3OS)+, 158 (C10H8NO)+, 156 (C10H8N2)+, 
148 (C9H10NO)+, 134 (C8H8NO)+, 130 (C9H8N)+, 106 
C7H8NO)+, 91 (C7H7)+.
N-Phenylethyl-2-{[5-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazol-2-yl]sulfanyl}acetamide (8d)
Brown colored and amorphous powder; Yield: 85%; 
m.p. 101 °C; Molecular formula: C21H20N4SO2; Molecular 
weight: 392 g/mol; IR (KBr) υmax: 3338 (N-H, stretching), 
3086 (C-H, str. of aromatic ring), 1657 (C=O str.), 1562 
(C=C, aromatic str.), 1668 (C=N, str. of oxadiazole ring), 
1063 (C-O-C bond str.), 633 (C-S bond str.); 1H-NMR 
(400 MHz): δ 11.03 (s, 1H, NH-1’), 8.74 (t, J = 5.6 Hz, 
TABLE 1 - Different R groups in 2-bromo-N-substitutedacetamides (8a-w)
Code R Code R Code R Code R
8a
 
8g
 
8m
 
8s
 
8b
 
8h
 
8n
 
8t
 
8c
 
8i
 
8o
 
8u
 
8d
 
8j
 
8p
 
8v
 
8e
 
8k
 
8q
 
8w
 
8f
 
8l
 
8r
 
 
K. Rubab, M. A. Abbasi, Aziz-ur-Rehman, S. Z. Siddiqui, M. Ashraf, A. Shaukat, I. Ahmad, M. A. Lodhi, F. A. Khan, M. Shahid, M. N Akhtar936
1H, NH-1’’’’), 7.48 (d, J = 8.0 Hz, 1H, H-4’), 7.38 (br.d, 
J = 8.0 Hz, 1H, H-7’), 7.33 ( br.s, 1H, H-2’), 7.29-7.26 
(m, 2H, H-3’’’ & H-5’’’), 7.23-7.19 (m, 3H, H-2’’’, H-6’’’ 
& H-4’’’), 7.08 ( t, J = 7.6 Hz, 1H, H-5’), 6.97 ( t, J = 6.9 
Hz, 1H, H-6’), 4.30 (s, 1H, H-10’), 4.26 ( br.s, 1H, H-2’’), 
4.05 ( t, J = 8.4 Hz, 2H, H-8’’’), 4.05 ( t, J = 8.0 Hz, 1H, 
H-7’’’); EIMS: m/z 394 (C21H20N4SO2+2)˙+ [M+2]+, 
392 (C21H20N4SO2)˙+ [M]+, 233 (C11H9N3OS+2)+, 231 
(C11H9N3OS)+, 162 (C10H12NO)+, )+, 158 (C10H8NO)+, 156 
(C10H8N2)+, 148 (C9H10NO)+, 130 (C9H8N)+, 120 (C7H8N)+, 
105 (C8H9)+, 91 (C7H7)+.
N-(2-Methylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazol-2-yl]sulfanyl}acetamide (8e)
Brownish grey colored amorphous powder; Yield: 
79%; m.p. 155 °C; Molecular formula: C20H18N4O2S; 
Molecular weight: 378 g/mol; IR (KBr) υmax: 3339 (N-
H, stretching), 3085 (C-H, str. of aromatic ring), 1651 
(C=O str.), 1565 (C=C, aromatic str.), 1663 (C=N, str. 
of oxadiazole ring), 1069 (C-O-C bond str.), 639 (C-S 
bond str.); 1H-NMR (300 MHz): δ 11.04 (s, 1H, NH-
1’), 9.69 (s, 1H, NH-1’’’’), 7.49 (d, J = 7.8 Hz, 1H, 
H-4’), 7.38 (br.d, J = 7.8 Hz, 1H, H-7’), 7.37-7.34 (m, 
2H, H-3’’’ & H-6’’’), 7.32 ( br.s, 1H, H-2’), 7.18 ( t, J = 
7.5 Hz, 1H, H-5’), 7.10-7.05 (m, 2H, H-4’’’ & H-5’’’), 
6.97 ( t, J = 7.5 Hz, 1H, H-6’), 4.32 (s, 1H, H-10’), 4.24 
(s, 2H, H-2’’), 2.16 (s, 3H, CH3-2’’’); EIMS: m/z 380 
(C20H18N4SO2+2)˙+ [M+2]+, 378 (C20H18N4SO2)˙+ [M]+, 233 
(C11H9N3OS+2)+, 231 (C11H9N3OS)+, 158 (C10H8NO)+, 156 
(C10H8N2)+, 148 (C9H10NO)+, 130 (C9H8N)+, 106, (C7H8N)+, 
91 (C7H7)+.
N-(3-Methylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazol-2-yl]sulfanyl}acetamide (8f)
Dark brown and sticky; Yield: 68%; Molecular 
formula: C21H20N4O2S; Molecular weight: 378 g/mol; 
IR (KBr) υmax: 3338 (N-H, stretching), 3086 (C-H, str. 
of aromatic ring), 1658 (C=O str.), 1568 (C=C, aromatic 
str.), 1663 (C=N, str. of oxadiazole ring), 1067 (C-O-C 
bond str.), 633 (C-S bond str.); 1H-NMR (400 MHz): δ 
11.03 (s, 1H, NH-1’), 8.89 ( s, 1H, NH-1’’’’), 7.48 (d, J = 
8.0 Hz, 1H, H-4’), 7.37 (br.d, J = 8.0 Hz, 1H, H-7’), 7.35 
(br.s, 1H, H-2’’’), 7.34 (br.d, J = 8.0 Hz, 1H, H-6’’’), 7.30 
(br.s, 1H, H-2’), 7.17 (t, J = 7.6 Hz, 1H, H-5’’’), 7.09 ( t, J 
= 7.6 Hz, 1H, H-5’), 7.03 ( t, J = 6.9 Hz, 1H, H-6’), 7.00 
(br.d, J = 8.0 Hz, 1H, H-4’’’), 4.31 (s, 1H, H-10’), 4.27 ( 
br.s, 1H, H-2’’), 2.30 (s, 3H, CH3-3’’’); EIMS: m/z 380 
(C20H18N4SO2)˙+ [M+2]+, 378 (C20H18N4SO2+2)˙+ [M]+, 
233 (C11H9N3OS+2)+, 231 (C11H9N3OS)+, 158 (C10H8NO)+, 
156 (C10H8N2)+, 148 (C9H10NO)+, 134 (C8H8NO)+, 130 
(C9H8N)+, 106, (C7H8N)+, 91 (C7H7)+.
N-(4-Methylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazol-2-yl]sulfanyl}acetamide (8g)
Light brown amorphous; Yield: 88%; m.p. 142 °C; 
Molecular formula: C21H20N4O2S; Molecular weight: 378 
g/mol; IR (KBr) υmax: 3339 (N-H, stretching), 3085 (C-H, 
str. of aromatic ring), 1655 (C=O str.), 1560 (C=C, aromatic 
str.), 1667 (C=N, str. of oxadiazole ring), 1065 (C-O-C bond 
str.), 637 (C-S bond str.); 1H-NMR (500 MHz): δ 11.03 (s, 
1H, NH-1’), 10.24 (s, 1H, NH-1’’’’), 7.50 (d, J = 8.0 Hz, 
1H, H-4’), 7.48 (d, J = 8.5 Hz, 2H, H-2’’’ & H-6’’’), 7.37 
(br.d, J = 8.5 Hz, 1H, H-7’), 7.32 ( br.s, 1H, H-2’), 7.12 (d, 
J = 7.5 Hz, 2H, H-3’’’ & H-5’’’), 7.09 ( t, J = 7.6 Hz, 1H, 
H-5’), 6.99 ( t, J = 6.9 Hz, 1H, H-6’), 4.30 (s, 1H, H-10’), 
4.19 ( br.s, 1H, H-2’’), 2.25 (s, 1H, CH3-4’’’); EIMS: m/z 380 
(C20H18N4SO2)˙+ [M+2]+, 378 (C20H18N4SO2+2)˙+ [M]+, 233 
(C11H9N3OS+2)+, 231 (C11H9N3OS)+, 158 (C10H8NO)+, 156 
(C10H8N2)+, 148 (C9H10NO)+, 134 (C8H8NO)+, 130 (C9H8N)+, 
106, (C7H8N)+, 91 (C7H7)+.
Methyl-2-[(2-{[5-(1H-indol-3-ylmethyl)-1,3,4-oxadiazol-
2-yl]sulfanyl}acetyl)amino]benzoate (8h)
Brown amorphous solid; Yield: 86%; m.p. 98 °C; 
Molecular formula: C21H18N4O2S; Molecular weight: 
422g/mol; IR (KBr) υmax: 3339 (N-H, stretching), 3085 
(C-H, str. of aromatic ring), 1654 (C=O str.), 1561 (C=C, 
aromatic str.), 1667 (C=N, str. of oxadiazole ring), 1067 
(C-O-C bond str.), 637 (C-S bond str.); 1H-NMR (500 
MHz): δ 11.02 (s, 1H, NH-1’), 8.20 (d, J = 8.5 Hz, 1H, 
H-3’’’), 7.90 (d, J = 7.5 Hz, 1H, H-6’’’), 7.61 (t, J = 7.0 
Hz, 1H, H-4’’’), 7.74 (d, J = 8.0 Hz, 1H, H-4’), 7.36 (d, 
J = 8.0 Hz, 1H, H-7’), 7.31 ( br.s, 1H, H-2’), 7.22 (t, J = 
7.0 Hz, 1H, H-5’’’), 7.08 ( t, J = 7.0 Hz, 1H, H-5’), 6.95 
( t, J = 7.0 Hz, 1H, H-6’), 4.32 (s, 1H, H-10’), 4.25 ( 
br.s, 1H, H-2’’), 3.75 (s, 3H, COOCH3-2’’’); EIMS: m/z 
424 (C21H18N4O4S)˙+ [M+2]+, 422 (C21H18N4O4S+2)˙+ 
[M]+, 393 (C20H15N4O3S+2)+, 233 (C11H9N3OS+2)+, 
231 (C11H9N3OS)+, 192 (C10H10NO3)+, 178(C9H8NO3)+, 
158 (C10H8NO)+ 156 (C10H8N2)+, 150 (C8H8NO2)+, 135 
(C8H7O2)+, 130 (C9H8N)+, 104 (C7H6N)+.
N-(2-Ethoxyphenyl)-2-{[5-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazol-2-yl]sulfanyl} acetamide (8i)
Dark brown sticky solid ; Yield: 74%; Molecular 
formula: C21H20N4O3S; Molecular weight: 408 g/mol; 
IR (KBr) υmax: 3338 (N-H, stretching), 3088 (C-H, str. of 
aromatic ring), 1658 (C=O str.), 1565 (C=C, aromatic str.), 
1666 (C=N, str. of oxadiazole ring), 1065 (C-O-C bond 
str.), 630 (C-S bond str.); 1H-NMR (400 MHz): δ 11.04 (s, 
1H, NH-1’), 9.94 ( s, 1H, NH-1’’’’), 7.46 (d, J = 7.2 Hz, 1H, 
H-4’), 7.36 (br.d, J = 7.6 Hz, 1H, H-7’), 7.30 ( br. s, 1H, 
H-2’), 7.29 (d, J = 7.6 Hz, 1H, H-6’’’),7.08 ( t, J = 7.6 Hz, 
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1H, H-5’), 7.04 ( t, J = 7.6 Hz, 1H, H-6’), 7.01-6.89 (m, 
3H, H-3’’’ to H-5’’’), 4.31 (s, 1H, H-10’), 4.26 ( br.s, 1H, 
H-2’’), 4.01 (q, J = 7.2 Hz, 2H, OCH2-2’’’), 1.44 (t, J = 6.8 
Hz, 3H, OCH2-CH3-2’’’); EIMS: m/z 410 (C21H20N4O3S)˙+ 
[M+2]+, 408 (C21H20N4O3S)˙+ [M]+, 233 (C11H9N3OS+2)+, 
231 (C11H9N3OS)+, 178 (C10H12NO2)+, 164 (C9H10NO2)+, 
158 (C10H8NO)+ 156 (C10H8N2)+ 136 (C9H10NO)+, 130 
(C9H8O)+, 121 (C8H9O)+.
N-(4-Ethoxyphenyl)-2-{[5-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazol-2-yl]sulfanyl} acetamide (8j)
Light brown amorphous solid; Yield: 87%; m.p. 
118 °C; Molecular formula: C21H20N4O3S; Molecular 
weight: 408 g/mol; IR (KBr) υmax: 3340 (N-H, stretching), 
3080 (C-H, str. of aromatic ring), 1658 (C=O str.), 1560 
(C=C, aromatic str.), 1667 (C=N, str. of oxadiazole ring), 
1065 (C-O-C bond str.), 633 (C-S bond str.); 1H-NMR (500 
MHz): δ 11.03 (s, 1H, NH-1’ ), 10.19 ( s,1H, NH-1’’’’), 7.50 
(d, J = 7.5 Hz, 1H, H-4’ ), 7.45 (d, J = 7.5 Hz, 1H, H-2’’’ & 
H-6’’’), 7.37 (br.d, J = 8.5 Hz, 1H, H-7’ ), 7.32 ( br.s, 1H, 
H-2’), 7.09 ( t, J = 8.0 Hz, 1H, H-5’), 6.99 ( t, J = 7.2 Hz, 
1H, H-6’), 6.87 (d, J = 7.5 Hz, 2H, H-3’’’ & H-5’’’), 4.33 
(s, 1H, H-10’), 4.21(s, 2H, H-2’’’’), 3.98 (quart. 2H, J = 7.0 
Hz, -OCH2- 4’’’), 1.31 (t, J = 7.0 Hz, 3H, OCH2-CH3-4’’’); 
( br.s, 1H, H-2’’), 4.01 (q, J = 7.2 Hz, 2H, OCH2-2’’’), 
1.44 (t, J = 6.8 Hz, 3H, OCH2-CH3-2’’’); EIMS: m/z 410 
(C21H20N4O3S)˙+ [M+2]+, 408 (C21H20N4O3S)˙+ [M]+, 233 
(C11H9N3OS+2)+, 231 (C11H9N3OS)+, 178 (C10H12NO2)+, 
164 (C9H10NO2)+, 158 (C10H8NO)+ 156 (C10H8N2)+ 136 
(C9H10NO)+, 130 (C9H8O)+, 121 (C8H9O)+.
N-(2-Ethylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazol-2-yl]sulfanyl} acetamide (8k)
Light brown amorphous solid; Yield: 85%; m.p. 
143 °C; Molecular formula: C21H20N4O2S; Molecular 
weight: 392 g/mol; IR (KBr) υmax: 3339 (N-H, stretching), 
3084 (C-H, str. of aromatic ring), 1657 (C=O str.), 1562 
(C=C, aromatic str.), 1665 (C=N, str. of oxadiazole ring), 
1064 (C-O-C bond str.), 637 (C-S bond str.); 1H-NMR 
(500 MHz,): δ 11.04 (s, 1H, NH-1’), 9.50 (s, 1H, NH-1’’’’), 
7.51 (d, J = 7.5 Hz, 1H, H-4’), 7.38 (br.d, J = 8.0 Hz, 1H, 
H-7’), 7.32-7.31 ( m, 2H, H-2’, H-6’’’), 7.23 ( dist. t, J 
= 6.0 Hz, 1H, H-5’’’), 7.18-7.15 (m, 2H, H-3’’’, H-4’’’), 
7.10 ( t, J = 7.0 Hz, 1H, H-5’), 6.99 ( t, J = 7.5 Hz, 1H, 
H-6’), 4.34 (s, 1H, H-10’), 4.25 ( br.s, 1H, H-2’’), 2.58 (q, 
J = 7.5 Hz, 2H, -CH2-2’’’), 1.43 (t, J = 7.5 Hz, 3H, -CH2-
CH3-2’’’); EIMS: m/z 394 (C21H20N4SO2+2)˙+ [M+2]+, 
392 (C21H20N4SO2)˙+ [M]+, 233 (C11H9N3OS+2)+, 231 
(C11H9N3OS)+, 162 (C10H12NO)+, )+, 158 (C10H8NO)+, 156 
(C10H8N2)+, 148 (C9H10NO)+, 130 (C9H8N)+, 120 (C7H8N)+, 
105 (C8H9)+, 79 (C6H7)+.
N-(4-Ethylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazol-2-yl]sulfanyl} acetamide (8l)
Brown amorphous solid; Yield: 68%; m.p. 124 °C; 
Molecular formula: C21H20N4O2S; Molecular weight: 392 
g/mol; IR (KBr) υmax: 3332 (N-H, stretching), 3079 (C-H, 
str. of aromatic ring), 1660 (C=O str.), 1563 (C=C, aromatic 
str.), 1667 (C=N, str. of oxadiazole ring), 1065 (C-O-C bond 
str.), 630 (C-S bond str.); 1H-NMR (400 MHz): δ 11.02 (s, 
1H, NH-1’), 9.96 ( s, 1H, NH-1’’’’), 7.48 (d, J = 8.0 Hz, 
1H, H-4’), 7.36 (br.d, J = 8.0 Hz, 1H, H-7’), 7.32 ( br.s, 1H, 
H-2’), 7.30 (d, J = 8.8 Hz, 1H, H-2’’’ & H-6’’’), 7.08 ( t, J = 
7.6 Hz, 1H, H-5’), 6.98 ( t, J = 7.6 Hz, 1H, H-6’), 6.90 (d, J = 
8.4 Hz, 2H, H-3’’’ & H-5’’’), 4.30 (s, 1H, H-10’), 4.21-3.87 
(m-overlapped, 4H, CH2-2’’ & -CH2-4’’’), 1.36 (t, J = 7.2 
Hz, 3H, -CH2-CH3-4’’’); EIMS: m/z 394 (C21H20N4SO2+2)˙+ 
[M+2]+, 392 (C21H20N4SO2)˙+ [M]+, 233 (C11H9N3OS+2)+, 
231 (C11H9N3OS)+, 162 (C10H12NO)+, 158 (C10H8NO)+, 156 
(C10H8N2)+, 148 (C9H10NO)+, 130 (C9H8N)+, 120 (C7H8N)+, 
105 (C8H9)+, 79 (C6H7)+.
N-(2-Methoxyphenyl)-2-{[5-(1H-indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl} acetamide (8m)
Dark brown amorphous solid; Yield: 90%; m.p. 
127 °C; Molecular formula: C20H18N4O3S; Molecular 
weight: 394 g/mol; IR (KBr) υmax: 3338 (N-H, stretching), 
3085 (C-H, str. of aromatic ring), 1658 (C=O str.), 1567 
(C=C, aromatic str.), 1665 (C=N, str. of oxadiazole ring), 
1065 (C-O-C bond str.), 632 (C-S bond str.); 1H-NMR (400 
MHz): δ 11.02 (s, 1H, NH-1’), 9.96 ( s, 1H, NH-1’’’’), 7.48 
(d, J = 8.0 Hz, 1H, H-4’), 7.36 (br.d, J = 8.0 Hz, 1H, H-7’), 
7.30 ( br.s, 1H, H-2’), 7.28 (d, J = 7.6 Hz, 1H, H-6’’’), 
7.08 ( t, J = 7.6 Hz, 1H, H-5’), 7.01-6.89 (m, 3H, H-3’’’ to 
H-5’’’), 6.98 ( t, J = 6.9 Hz, 1H, H-6’), 4.30 (s, 1H, H-10’), 
4.26 ( br.s, 1H, H-2’’), 4.01 (s, 3H, OCH3-2’’’); EIMS: 
m/z 396 (C20H18N4O3S+2)˙+ [M+2]+, 394 (C20H18N4O3S)˙+ 
[M]+, 233 (C11H9N3OS+2)+, 231 (C11H9N3OS)+, 164 
(C9H10NO2)+, 158 (C10H8NO)+, 156 (C10H8N2)+, 150 
(C8H8NO2)+, 130 (C9H8N)+, 122 (C7H8NO)+, 107 (C7H7O)+.
N-(2,3-Dimethylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl} acetamide (8n)
Dark brown amorphous solid; Yield: 98%; m.p. 118 
°C; Molecular formula: C21H20N4O2S; Molecular weight: 
392.48 g/mol; IR (KBr) υmax: 3343 (N-H, stretching), 3078 
(C-H, str. of aromatic ring), 1649 (C=O str.), 1566 (C=C, 
aromatic str.), 1660 (C=N, str. of oxadiazole ring), 1065 
(C-O-C bond str.), 634 (C-S bond str.); 1H-NMR (400 
MHz): δ 11.02 (s, 1H, NH-1’), 9.94 ( s, 1H, NH-1’’’’), 7.48 
(d, J = 8.4 Hz, 1H, H-4’), 7.36 (br.d, J = 8.4 Hz, 1H, H-7’), 
7.34 ( br.s, 1H, H-2’), 7.31 (br.d, J = 7.6 Hz, 1H, H-6’’’), 
7.09 ( t, J = 7.6 Hz, 1H, H-5’), 7.06 (br.t, J = 7.2 Hz, 1H, 
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H-5’’’),6.98 ( t, J = 7.2 Hz, 1H, H-6’), 6.96-6.94 (m, 1H, 
H-4’’’), 4.30 (s, 1H, H-10’), 4.28 ( br.s, 1H, H-2’’), 2.25 
(s, 3H, CH3-2’’’), 2.14 (s, 3H, CH3-3’’’); EIMS: m/z 394 
(C21H20N4O2S)˙+ [M+2]+, 392 (C21H20N4O2S)˙+ [M]+, 233 
(C11H9N3OS+2)+, 231 (C11H9N3OS)+, 162 (C10H12NO)+, 
158 (C10H8NO)+, 156 (C10H8N2)+, 148 (C9H10NO)+, 130 
(C9H8N)+, 120 (C8H10N)+, 105 (C8H9)+.
N-(2,4-Dimethylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl} acetamide (8o)
Dark brown amorphous solid; Yield: 88%; m.p. 153 
°C; Molecular formula: C21H20N4O2S; Molecular weight: 
392.48 g/mol; IR (KBr) υmax: 3339 (N-H, stretching), 3085 
(C-H, str. of aromatic ring), 1657 (C=O str.), 1561 (C=C, 
aromatic str.), 1667 (C=N, str. of oxadiazole ring), 1065 
(C-O-C bond str.), 637 (C-S bond str.); 1H-NMR (400 
MHz): δ 11.03 (s, 1H, NH-1’), 9.97 ( s, 1H, NH-1’’’’), 
7.49 (d, J = 8.0 Hz, 1H, H-4’), 7.36 (br.d, J = 7.6 Hz, 1H, 
H-7’), 7.31 ( br.s, 1H, H-2’), 7.29 (br.d, J = 9.2 Hz, 1H, 
H-6’’’), 7.09 ( t, J = 7.6 Hz, 1H, H-5’), 7.07 (br.d, J = 8.4 
Hz, 1H, H-5’’’), 7.02 (s, 1H, H-3’’’), 6.98 ( t, J = 6.8 Hz, 
1H, H-6’), 4.30 (s, 1H, H-10’), 4.26 ( br.s, 1H, H-2’’), 2.30 
(s, 3H, CH3-2’’’), 1.52 (s, 3H, CH3-4’’’); EIMS: m/z 394 
(C21H20N4O2S)˙+ [M+2]+, 392 (C21H20N4O2S)˙+ [M]+, 233 
(C11H9N3OS+2)+, 231 (C11H9N3OS)+, 162 (C10H12NO)+, 
158 (C10H8NO)+, 156 (C10H8N2)+, 148 (C9H10NO)+, 130 
(C9H8N)+, 120 (C8H10N)+, 105 (C8H9)+.
N-(2,5-Dimethylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl} acetamide (8p)
Dark brown amorphous solid; Yield: 86%; m.p. 126 
°C; Molecular formula: C21H20N4O2S; Molecular weight: 
392.48 g/mol; IR (KBr) υmax: 3336 (N-H, stretching), 3088 
(C-H, str. of aromatic ring), 1657 (C=O str.), 1560 (C=C, 
aromatic str.), 1667 (C=N, str. of oxadiazole ring), 1065 
(C-O-C bond str.), 636 (C-S bond str.); 1H-NMR (400 
MHz): δ 11.04 (s, 1H, NH-1’), 9.98 ( s, 1H, NH-1’’’’), 
7.47 (d, J = 7.6 Hz, 1H, H-4’), 7.36 (br.d, J = 7.6 Hz, 1H, 
H-7’), 7.31 ( br.s, 1H, H-2’), 7.29 (s, 1H, H-6’’’), 7.09 ( t, 
J = 7.6 Hz, 1H, H-5’), 7.07 (br.d, J = 8.0 Hz, 1H, H-3’’’), 
7.02(br.d, J = 8.4 Hz, 1H, H-4’’’), 6.98 ( t, J = 6.8 Hz, 1H, 
H-6’), 4.30 (s, 1H, H-10’), 4.26 ( br.s, 1H, H-2’’), 2.30 
(s, 3H, CH3-2’’’), 1.52 (s, 3H, CH3-5’’’); EIMS: m/z 394 
(C21H20N4O2S)˙+ [M+2]+, 392 (C21H20N4O2S)˙+ [M]+, 233 
(C11H9N3OS+2)+, 231 (C11H9N3OS)+, 162 (C10H12NO)+, 
158 (C10H8NO)+, 156 (C10H8N2)+, 148 (C9H10NO)+, 130 
(C9H8N)+, 120 (C8H10N)+, 105 (C8H9)+.
N-(2,6-Dimethylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl} acetamide (8q)
Brown amorphous solid; Yield: 90%; m.p. 146 °C; 
Molecular formula: C21H20N4O2S; Molecular weight: 
394.48 g/mol; IR (KBr) υmax: 3339 (N-H, stretching), 
3088 (C-H, str. of aromatic ring), 1653 (C=O str.), 1560 
(C=C, aromatic str.), 1661 (C=N, str. of oxadiazole ring), 
1065 (C-O-C bond str.), 630 (C-S bond str.); 1H-NMR 
(400 MHz): δ 11.02 (s, 1H, NH-1’), 9.96 ( s, 1H, NH-
1’’’’), 7.48 (d, J = 8.0 Hz, 1H, H-4’), 7.36 (br.d, J = 8.0 
Hz, 1H, H-7’), 7.30 ( br.s, 1H, H-2’), 7.08 ( t, J = 7.6 Hz, 
1H, H-5’), 7.05-7.03 (m, 3H, H-3’’’ to H-5’’’), 6.98 ( t, J 
= 6.9 Hz, 1H, H-6’), 4.30 (s, 1H, H-10’), 4.26 (br.s, 1H, 
H-2’’), 2.16 (s, 6H, CH3-2’’’ & CH3-6’’’); EIMS: m/z 394 
(C21H20N4O2S)˙+ [M+2]+, 392 (C21H20N4O2S)˙+ [M]+, 233 
(C11H9N3OS+2)+, 231 (C11H9N3OS)+, 162 (C10H12NO)+, 
158 (C10H8NO)+, 156 (C10H8N2)+, 148 (C9H10NO)+, 130 
(C9H8N)+, 120 (C8H10N)+, 105 (C8H9)+.
N-(3,4-Dimethylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl} acetamide (8r)
Dark brown amorphous solid; Yield: 81%; m.p. 
140°C; Molecular formula: C21H20N4O2S; Molecular weight: 
392.48 g/mol; IR (KBr) υmax: 3342 (N-H, stretching), 3084 
(C-H, str. of aromatic ring), 1659 (C=O str.), 1559 (C=C, 
aromatic str.), 1667 (C=N, str. of oxadiazole ring), 1069 
(C-O-C bond str.), 637 (C-S bond str.); 1H-NMR (400 
MHz): δ 11.03 (s, 1H, NH-1’), 10.16 ( s, 1H, NH-1’’’’), 7.50 
(d, J = 7.5 Hz, 1H, H-4’), 7.35 (br.d, J = 8.5 Hz, 1H, H-7’), 
7.31 (s, 1H, H-2’’’), 7.30 ( br.s, 1H, H-2’), 7.24 (br.d, J = 8.0 
Hz, 1H, H-6’’’), 7.08 ( t, J = 8.0 Hz, 1H, H-5’), 7.04 (br.d, 
J = 8.0 Hz, 1H, H-5’’’), 6.97 ( t, J = 8.0 Hz, 1H, H-6’), 4.30 
(s, 1H, H-10’), 4.18 ( br.s, 1H, H-2’’), 2.16 (s, 3H, CH3-3’’’), 
2.12 (s, 3H, CH3-4’’’); EIMS: m/z 394 (C21H20N4O2S)˙+ 
[M+2]+, 392 (C21H20N4O2S)˙+ [M]+, 233 (C11H9N3OS+2)+, 
231 (C11H9N3OS)+, 162 (C10H12NO)+, 158 (C10H8NO)+, 156 
(C10H8N2)+, 148 (C9H10NO)+, 130 (C9H8N)+, 120 (C8H10N)+, 
105 (C8H9)+.
N-(3,5-Dimethylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl} acetamide (8s)
Brownish grey amorphous solid; Yield: 79%; m.p. 
99 °C; Molecular formula: C21H20N4O2S; Molecular 
weight: 392.48 g/mol; IR (KBr) υmax: 3340 (N-H, 
stretching), 3087 (C-H, str. of aromatic ring), 1658 
(C=O str.), 1560 (C=C, aromatic str.), 1669 (C=N, str. of 
oxadiazole ring), 1065 (C-O-C bond str.), 636 (C-S bond 
str.); 1H-NMR (400 MHz): δ 11.03 (s, 1H, NH-1’), 9.98 ( 
s, 1H, NH-1’’’’), 7.49 (d, J = 8.0 Hz, 1H, H-4’), 7.36 (br.d, 
J = 8.0 Hz, 1H, H-7’), 7.30 ( br.s, 1H, H-2’), 7.16 (br.s, 
2H, H-2’’’ & H-6’’’), 7.08 ( t, J = 7.2 Hz, 1H, H-5’), 6.98 
( t, J = 7.6 Hz, 1H, H-6’), 6.72 (br.s, 1H, H-4’’’), 4.32 (s, 
1H, H-10’), 4.25 ( br.s, 1H, H-2’’), 2.93 (s, 3H, CH3-3’’’), 
2.85 (s, 3H, CH3-5’’’); ); EIMS: m/z 394 (C21H20N4O2S)˙+ 
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[M+2]+, 392 (C21H20N4O2S)˙+ [M]+, 233 (C11H9N3OS+2)+, 
231 (C11H9N3OS)+, 162 (C10H12NO)+, 158 (C10H8NO)+, 
156 (C10H8N2)+, 148 (C9H10NO)+, 130 (C9H8N)+, 120 
(C8H10N)+, 105 (C8H9)+.
N-(5-Chloro-2-methylphenyl)-2-{[5-(1H-indol-3-
ylmethyl)-1,3,4-oxadizol-2yl]sulfanyl} acetamide (8t)
Brown amorphous solid; Yield: 78%; m.p. 110 
°C; Molecular formula: C20H17N4SO3Cl; Molecular 
weight: 428.5 g/mol; HR-MS: IR (KBr) υmax: 3333 (N-
H, stretching), 3087 (C-H, str. of aromatic ring), 1659 
(C=O str.), 1566 (C=C, aromatic str.), 1670 (C=N, str. of 
oxadiazole ring), 1060 (C-O-C bond str.), 637 (C-S bond 
str.); 1H-NMR (500 MHz): δ 11.11 (s, 1H, NH-1’), 9.96 
(s, 1H, NH-1’’’’), 8.11-7.95 (m, 2H, H-6’’’, H-4’’’), 7.50 
(d, J = 7.5 Hz, 1H, H-4’), 7.37 (d, J = 8.0 Hz, 1H, H-7’), 
7.33 ( br. s, 1H, H-2’), 7.13 (d, J = 8.5 Hz, 1H, H-3’’’), 
7.11 ( t, J = 7.5 Hz, 1H, H-5’), 6.98 ( t, J = 7.5 Hz, 1H, 
H-6’), 4.33 (s, 1H, H-10’), 3.84 (s, 2H, H-2’’), 2.89 (s, 
3H, -OCH32’’’); EIMS: m/z 432 (C20H17N4O3SCl+4)˙+ 
[M+4]+,  430 (C20H17N4O3SCl+2)˙+ [M+2]+,  428 
(C20H17N4O3SCl)˙+ [M]+, 233 (C11H9N3OS+2)+, 231 
(C11H9N3OS)+, 200 (C9H9NO2Cl+2)+, 198 (C9H9NO2Cl)+, 
186 (C8H7NO2Cl+2)+, 184 (C8H7NO2Cl)+, 158 (C10H8NO)+, 
158 (C7H7NOCl+2)+, 156 (C7H7NOCl)+, 156 (C10H8N2)+, 
143(C7H6OCl+2)+, 141(C7H6OCl)+, 130 (C9H8N)+. 
N-(2-Ethoxy-6-methylphenyl)-2-{[5-(1H-indol-3-
ylmethyl)-1,3,4-oxadiazol-2yl]sulfanyl} acetamide (8u)
Light brown amorphous solid; Yield: 88%; m.p. 138 
°C; Molecular formula: C22H22N4O3S; Molecular weight: 
422 g/mol; HR-MS: IR (KBr) υmax: 3338 (N-H, stretching), 
3084 (C-H, str. of aromatic ring), 1654 (C=O str.), 1563 
(C=C, aromatic str.), 1669 (C=N, str. of oxadiazole ring), 
1068 (C-O-C bond str.), 637 (C-S bond str.); 1H-NMR 
(300 MHz,): δ 11.04 (s, 1H, NH-1’), 9.64 (s, 1H, NH-1’’’’), 
7.49 ( br.d, J = 7.8 Hz, 1H, H-4’), 7.36 (br.d, J = 8.1 Hz, 
1H, H-7’), 7.32 ( br.s, 1H, H-2’), 7.08 ( t, J = 6.9 Hz, 1H, 
H-5’), 7.05-7.03 (m, 3H, H-3’’’ to H-5’’’), 6.98 ( t, J = 7.5 
Hz, 1H, H-6’), 4.32 (s, 1H, H-10’), 4.22 (s, 2H, H-2’’), 
2.49-2.45( m. 2H,merged in signal of DMSO-d6, -OCH2-
CH3-2’’’), 2.06 (s, 3H, CH3-6’’’) 1.01 (t, 3H, -OCH2-
CH3-2’’’ ); EIMS: m/z 408 (C22H22N4O2S+2)˙+ [M+2]+, 
406 (C22H22N4O2S)˙+ [M], 233 (C11H9N3OS+2)+, 231 
(C11H9N3OS)+, 178 (C10H12NO2)+, 158 (C10H8NO)+, 156 
(C10H8N2)+, 135 (C9H12N)+, 130 (C9H8O)+, 119 (C9H11)+, 
104 (C7H6N)+, 79 (C7H6N)+.
N-(2-Methyl-6-nitrophenyl)-2-{[5-(1H-Indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl}acetamide (8v)
Light brown amorphous powder; Yield: 92%; m.p. 
192 °C; Molecular formula: C20H17N5O4S Molecular 
weight: 423 g/mol; IR (KBr) υmax: 3332 (N-H, stretching), 
3085 (C-H, str. of aromatic ring), 1655 (C=O str.), 1561 
(C=C, aromatic str.), 1667 (C=N, str. of oxadiazole ring), 
1065 (C-O-C bond str.), 637 (C-S bond str.); 1H-NMR (300 
MHz,): δ 11.02 (s, 1H, NH-1’), 10.26 (s, 1H, NH-1’’’’), 
7.74 (d, J = 8.0 Hz, 1H, H-5’’’), 7.59 ( br.d, J = 7.6 Hz, 1H, 
H-4’), 7.48 (br.d, J = 7.6 Hz, 1H, H-7’ ), 7.39 (d, J = 8.0 
Hz, 1H, H-3’’’), 7.35 (d, J = 8.0 Hz, 1H, H- H-4’’’), 7.31 ( 
br.s, 1H, H-2’), 7.08 ( t, J = 6.9 Hz, 1H, H-5’), 6.97 ( t, J = 
7.5 Hz, 1H, H-6’), 4.32 (s, 1H, H-10’), 4.22 (s, 2H, H-2’’), 
2.24 ( s, 3H, -CH3-2’’’); EIMS: m/z 425 (C20H17N5SO4+2)˙+ 
[M+2]+, 423 (C20H17N5SO4)˙+ [M]+, 233 (C11H9N3OS+2)+, 
231 (C11H9N3OS)+, 193 (C9H9N2O3)+, 179 (C8H7N2O3)+, 
158 (C10H8NO)+, 156 (C10H8N2)+, 151 (C7H7N2O2)+, 130 
(C9H8N)+, 136 (C7H6NO2)+.
N-(4-methyl-2-pyridinyl)-2-{[5-(1H-indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl} acetamide (8w)
Dark purple amorphous powder; Yield: 83%; m.p. 
206 °C; Molecular formula: C19H17N5O2S; Molecular 
weight: 379 g/mol; IR (KBr) υmax: 3345 (N-H, stretching), 
3081 (C-H, str. of aromatic ring), 1657 (C=O str.), 1563 
(C=C, aromatic str.), 1669 (C=N, str. of oxadiazole ring), 
1065 (C-O-C bond str.), 637 (C-S bond str.); 1H-NMR 
(400 MHz): δ 11.02 (s, 1H, NH-1’), 9.96 ( s, 1H, NH-
1’’’’), 8.01 (d, J = 7.2 Hz, 1H, H-6’’’), 7.48 (d, J = 8.4 Hz, 
1H, H-4’), 7.36 (br.d, J = 8.0 Hz, 1H, H-7’), 7.30 (br.s, 
1H, H-2’), 7.14 (s, 1H, H-3’’’), 7.09 (d, J = 7.2 Hz, 1H, 
H-5’’’), 7.08 ( t, J = 7.6 Hz, 1H, H-5’), 6.98 (t, J = 6.9 Hz, 
1H, H-6’), 4.30 (s, 1H, H-10’), 4.26 ( br.s, 1H, H-2’’), 
2.40 (s, 3H, CH3-4’’’); EIMS: m/z 381 (C19H17N5O2S+2)˙+ 
[M+2]+, 379 (C19H17N5O2S)˙+ [M]+, 233 (C11H9N3OS+2)+, 
231 (C11H9N3OS)+, 158 (C10H8NO)+, 156 (C10H8N2)+, 
149 (C8H9N2O)+, 135 (C7H7N2O)+, 130 (C9H8N)+, 107 
(C6H7N2)+.
Biological screening
Lipoxygenase (LOX) assay
Lipoxygenase activity was assayed according to the 
reported methods (Tappel, 1953; Evans, 1987; Baylac, 
Racine, 2003).
α-Glucosidase assay
α-Glucosidase inhibitory activity was evaluated 
according to the cited method (Pierre et al., 1978).
Butyrylcholinesterase (BChE) assay
The BChE inhibition activity was performed 
according to the reported method (Ellman et al., 1961).
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Antibacterial activity
The antibacterial activity was performed in sterile 
96-wells micro plates under aseptic environments. The 
method is based on the principle that microbial cell number 
increases as the microbial growth proceeds in a log phase 
of growth which results in increased absorbance of broth 
medium (Kaspady et al., 2009; Yang et al., 2006).
Hemolytic activity assay
Hemolytic activity of the compounds was performed 
by the reported methods (Shahid et al., 2013; Zuber et al., 
2014).
Statistical analysis
All the measurements were carried out in triplicate 
and statistical analysis was performed by Microsoft Excel 
2010. The results are presented as mean ± SEM with 90% 
CL.
Molecular docking methodology
To predict the bioactive conformations, various 
compounds (ligands) were docked into the binding pockets 
of the selected proteins (enzymes) by using the default 
parameters of MOE-Dock program.
Prior to docking, the protein molecules of 
α-glucosidase, lipoxygenase and butyrylcholinesterase 
were retrieved from Protein Data Bank having PDB ID 
codes of 3NO4 (Resolution: 2.02Å), 1IK3 (Resolution: 
2.0Å) and 1POP (Resolution: 2.0Å) respectively. All the 
water molecules were removed from receptor proteins and 
3D protonation was carried out by using the Protonate 3D 
Option. The energies of protein molecules were minimized 
by using the default parameters of MOE 2009-10 energy 
minimization algorithm (gradient: 0.05, Force Field: 
MMFF94X). Then all the ligands were docked into the 
binding pockets (selective residues/amino acids as shown 
in the docking images) of the above mentioned proteins 
using Triangular Matching docking method. Re-docking 
procedure was also applied to validate the docking protocol. 
Each complex was analyzed for the type of interactions; 
bond distances and their 3D images were taken.
RESULTS AND DISCUSSION
We report herein the synthesis of some new N-substituted 
derivatives of 2-{[5-(1H-indol-3-ylmethyl)-1,3,4-oxadiazol-
2-yl]sulfanyl}acetamides. These synthesized compounds 
were evaluated for their antibacterial and hemolytic activity. 
Enzyme inhibition activity was well supported by molecular 
docking results. The reaction sequence leading to the 
preparation of the desired heterocyclic compounds is outlined 
in Scheme 1. 5-(1H-Indole-3-yl-methyl)-1,3,4-oxadiazole-
2-thiol was prepared by converting 2-(1H-Indol-3-yl)acetic 
acid (1) to its corresponding ester 2 in ethanol, which was 
used in excess as solvent to shift this reversible reaction in 
the forward direction, where H2SO4 was used as catalyst. 
Aqueous Na2CO3 was used to neutralize the catalyst and 
unreacted acid (1). Ester 2, on further reaction with hydrazine 
monohydrate, yielded acid hydrazide 3 after 3 h stirring at 
room temperature. This reaction readily occurred, otherwise 
a few drops of glacial acetic acid was added to speed up this 
reaction. The hydrazide (3) was cyclized to 5-(1H-indole-3-
yl-methyl)-1,3,4-oxadiazole-2-thiol (4) in the presence of 
CS2 and alcoholic KOH with refluxing for 6 h. CS2 is volatile 
and is used in double quantity compared to 4 to favor product 
formation. KOH was used to facilitate the delocalization of 
negative charge during intramolecular cyclization to form 4. 
A series of N-substituted 2-bromoacetmaide derivatives were 
also synthesized by manually shaking equimolar amounts of 
bromoacetyl bromide (VI) with different substituted amines 
(Va-w) in 10% aqueous Na2CO3 (pH 8-9). Amines with 
electron-donating groups were more active in nucleophilic 
reactions than those with electron-withdrawing groups. 
These N-substituted 2-bromoacetmaide derivatives (7a-w) 
were reacted further with 5-(1H-indole-3-yl-methyl)-1,3,4-
oxadiazole-2-thiol (4) in NaH as weak base and DMF as 
aprotic medium to produce 2-{[5-(1H-indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl}acetamides (8a-w), where 
complete conversion was achieved within almost 8 h by 
stirring with 68-98% yields, as outlined in Scheme 1 (Sabahat 
et al., 2013). The products were isolated by adding ice-cold 
water to the reaction mixture and filtering off the precipitated 
solid. In some cases, the compound was obtained with the 
solvent extraction method using chloroform/ethyl acetate. 
The structure of the parent compound and its derivatives were 
confirmed by IR, 1H-NMR, and EI-MS data, as described in 
the experimental section.
Compound 8g was obtained as a light-brown 
amorphous powder with 88% yield and m.p. 142 °C. 
The molecular formula C21H20N4O2S was ascertained by 
EI-MS data which revealed an [M]+ ion peak at m/z 378 
and by the assigned protons in the 1H-NMR spectrum. IR 
spectrum further revealed characteristic peaks at 3339 cm-1 
for N-H stretch of the indole moiety, 3085 cm-1 for aromatic 
C-H stretching, 1667 cm-1 for C=N stretching due to the 
presence of the oxadiazole ring, 1560 cm-1 for stretching 
of C=C phenyl rings of indole and N- substituted aromatic 
ring, 1655 cm-1 for stretching of C=O, 1065 cm-1 for C-O-C 
bond stretching of oxadiazole ring and 637 cm-1 for C-S 
stretching. EIMS data further supported the structure 
by revealing a base peak at m/z 130 for (C9H8N)+ of the 
indole moiety and of major fragments given in Figure 2. In 
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FIGURE 3 - H NMR spectrum of 8g.
1H-NMR, spectrum signals of the indole moiety appeared 
at δ 11.03 (s, 1H, NH-1’), 7.50 (d, J = 8.0 Hz, 1H, H-4’), 
7.37 (br.d, J = 8.5 Hz, 1H, H-7’), and two ortho coupled 
triplets with integration of one proton each appeared at 
δ 7.09 for H-5’ and δ H-6’, respectively, In the aromatic 
region, a broad singlet appeared at δ 7.32 of H-2’, and the 
last signal for the indole moiety appeared in the aliphatic 
region with integration of two protons at δ 4.30 of H-10’. 
The acetamide part of the molecule gave a deshielded 
singlet of –NH of amide at δ 10.24 for NH-1’’’’, doublet in 
aromatic region at δ 7.48 of H-2’’’ & H-6’’’ and two other 
protons of this ring gave a doublet at δ 7.12 of H-3’’’ & 
H-5’’’. Two more singlets appeared in the aliphatic region 
with integration of two protons at δ 4.19 of H-2” and with 
three protons at δ 2.25 for CH3-4”’ (Figure 3). On the basis 
of this spectral evidence, the structure was determined 
FIGURE 2 - Mass fragmentation pattern of N-(3-methylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-1,3,4- oxadiazol-2-yl]sulfanyl}
acetamide (8g)
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as N-(4-methylphenyl)-2-{[5-(1H-indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl}acetamide (8g). Similarly, 
the structures of other derivatives of 5-(1H-indole-3-
ylmethyl)-1,3,4-oxadiazole-2-thiol were elucidated in the 
same way, as described in the experimental section.
Biological screening
Enzyme inhibition activity
In vitro evaluation of the enzyme inhibitory 
potential of N-substituted 2-{[5-(1H-indol-3-ylmethyl)-
1,3,4-oxadiazol-2-yl]sulfanyl}acetamides (8a-w) against 
α-glucosidase, BChE and LOX revealed that these 
molecules exhibited variable inhibitory potential as 
shown by their % inhibition and IC50 values (Table II). 
Compound 8q showed better inhibition of α-glucosidase 
with IC50 of 49.71 ± 0.19 µM as compared to standard 
acarbose (38.25 ± 0.12 µM); 8d, 8p and 8t also exhibited 
comparable inhibition, and other compounds showed weak 
or no inhibitory effect against α-glucosidase. Compounds 
8g and 8h showed almost similar inhibitory potential 
against BChE, with IC50 values of 31.62 ± 0.16 and 33.70 
± 0.95 µM, respectively, which were better than other 
compounds of the series. Against LOX, compound 8b 
revealed maximum inhibition at at 99.30 ± 2.89 µM, which 
was almost five times higher than that for the standard 
baicalein (22.4 ± 1.30 µM). The other compounds showed 
weak or no inhibition of this enzyme.
Antibacterial activity
All synthesized N-substituted 2-{[5-(1H-indol-
3-ylmethyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetamides 
TABLE - II Enzyme Inhibition activity of N-substituted 2-{[5-(1H-indol-3-ylmethyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetamides 
(8a-w)
Compound
α-Glucosidase BChE LOX
Inhibition (%) IC50 (µM) Inhibition (%) IC50 (µM) Inhibition (%) IC50 (µM)
8a 81.26±2.15 435.3±2.81 81.67±1.97 345.2±1.46 53.87±1.76 >500
8b 78.91±1.84 411.6±1.89 70.92±0.51 74.51±1.65 58.30±0.13 99.3±2.89
8c 12.92±0.12 - 64.17±2.16 270.3±1.67 60.21±1.56 387±1.22
8d 97.73±1.86 52.77±0.09 86.67±1.05 35.90±0.18 49.25±0.26 >500
8e 96.53±1.92 111.9±1.12 63.21±1.47 75.23±2.86 77.37±0.45 298±0.12
8f 98.12±2.14 73.97±0.96 83.8±1.28 63.91±0.91 62.09±1.55 307±0.89
8g 94.56±1.28 150.4±2.57 82.53±2.47 31.62±0.16 78.6±1.20 261±1.93
8h 81.56±1.32 205.5±2.93 84.33±3.06 33.70±0.95 - -
8i 79.62±1.25 201.2±2.65 87.92±0.64 335.1±1.77 81.86±1.05 296±0.44
8j 23.72±0.17 - 84.42±0.18 140.2±2.83 39.20±1.23 -
8k 98.19±2.43 89.43±1.12 91.17±0.99 69.80±0.62 66.60±1.55 176±0.90
8l 94.17±1.29 355.2±2.38 85.08±0.40 158.2±3.27 67.62±1.03 137±1.90
8m 17.39±0.12 - 76.50±3.46 265.3±2.72 70.37±1.23 324±0.89
8n 92.91±1.17 181.7±2.31 73.92±0.24 234.0±0.56 - -
8o 99.81±1.22 115.4±1.32 87.00±2.98 338.0±3.73 94.37±2.87 185±0.34
8p 80.21±1.29 54.84±0.14 74.12±1.46 80.21±1.96 65.10±1.22 372±0.99
8q 97.89±1.95 49.71±0.19 66.67±3.02 128.4±0.47 48.40±2.90 >500
8r 92.91±2.17 109.1±1.38 87.50±1.69 60.38±0.60 64.25±1.22 317±1.90
8s 81.76±1.95 91.27±0.58 86.33±3.15 60.12±2.59 83.61±0.98 273±2.45
8t 91.65±1.93 54.25±0.17 72.40±2.57 70.70±0.39 62.64±0.72 141±1.78
8u 9.17±0.11 - 83.00±0.25 72.91±2.50 50.90±2.08 >500
8v 97.26±1.23 116.5±1.31 91.67±2.67 143.2±1.94 49±0.78 >500
8w 83.69±1.92 178.8±2.81 78.75±3.14 360.0±0.47 66.7±0.87 311±1.36
Control Acarbose Eserine Baicalein
38.25±0.12 0.85±0.01 22.4±1.3
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(8a-w) were screened for antibacterial activity against 
two Gram-positive, Bacillus subtilis and Staphylococcus 
aureus, and three Gram-negative strains, Salmonella 
typhi, Escherichia coli and Pseudomonas aeruginosa. 
Most of the synthesized compounds exhibited very 
good inhibitory potential, as depicted by their MIC 
values. Ciprofloxacin was used as reference standard 
in this study (Table III). Compounds 8c and 8d showed 
very good inhibitory potential against all the bacterial 
strains used in this study, especially compound 8c with 
MIC values of 9.75 ± 3.57 and 9.15 ± 4.12 µM against 
S. typhi and S. aureus, respectively, which were very 
close to the standard, ciprofloxacin. Compound 8b also 
revealed very good antibacterial activity (MIC of 9.84 ± 
2.99 µM) against S. typhi, while 8d, 8n and 8p showed 
good inhibitory effect against E. coli with MIC values 
of 10.45 ± 1.80, 10.48 ± 2.00 and 10.50 ± 2.65 µM 
respectively. Compounds 8c and 8f also exhibited good 
inhibition against P. aeruginosa. Against B. subtilis, 8f, 
8g, 8o and 8v showed MIC values of 10.78 ± 1.08, 10.33 
± 3.00, 10.56 ± 2.90, and 10.97 ± 2.14 µM respectively, 
while 8c and 8l again showed very good antibacterial 
potential against S. aureus, with MIC values very close 
to that for ciprofloxacin (9.15 ± 4.12, and 9.96 ± 3.58 µM, 
respectively). The other compounds showed moderate 
antibacterial potential as a whole.
Hemolytic activity
The lowest hemolytic activity (Table IV) was 
exhibited by 8p (1.67%), 8t (2.16%) and 8u (2.93%). The 
TABLE III - Antibacterial activity (MIC) of N-substituted 2-{[5-(1H-indol-3-ylmethyl)- 1,3,4-oxadiazol-2-yl]sulfanyl}acetamides 
(8a-w)
Compounds
MIC (µM)
S. typhi E. coli P. aeruginosa B. subtilis S. aureus
8a 10.66±2.34 13.50±1.41 11.68±2.29 12.65±1.29 10.42±3.00
8b 9.84±2.99 14.75±2.78 16.41±1.67 13.20±1.77 10.43±3.55
8c 9.75±3.57 12.19±1.76 10.37±2.65 12.22±1.14 9.15±4.12
8d 10.50±2.54 10.45±1.80 12.12±1.25 11.76±1.90 11.36±2.48
8e 10.00±1.87 18.17±1.54 14.70±2.17 19.93±4.00 11.95±1.37
8f 12.54±1.55 12.45±3.24 10.50±3.00 10.78±1.08 11.14±1.87
8g 11.39±2.37 11.07±1.09 12.39±3.67 10.33±3.00 11.87±2.59
8h 12.63±2.12 13.87±2.22 11.06±0.25 11.45±5.00 12.33±2.43
8i 13.21±1.88 12.04±1.49 12.03±1.00 13.11±1.11 11.24±2.00
8j 13.17±2.00 17.57±1.57 15.60±2.36 19.65±1.48 13.61±2.44
8k 12.01±0.58 15.23±2.32 12.85±1.42 17.91±1.19 13.17±1.41
8l 11.97±1.77 17.58±2.13 13.96±2.58 14.41±2.12 9.96±3.58
8m 10.47±2.12 - 16.32±5.00 - 11.53±2.99
8n 10.53±0.61 10.48±2.00 11.49±1.42 13.58±2.04 11.18±2.56
8o 11.07±2.22 11.16±1.44 11.39±2.33 10.56±2.90 10.73±1.90
8p 11.18±1.48 10.50±2.65 13.23±1.83 17.14±1.29 10.87±0.69
8q 10.45±1.78 13.91±1.86 14.64±4.86 11.58±1.44 11.04±1.66
8r 10.41±2.65 11.50± 1.90 14.57±1.17 14.67±2.16 10.48±2.87
8s 11.27±1.07 - 16.36±1.83 - 10.65±1.16
8t 15.63±0.90 16.74±1.96 17.32±1.00 12.80±2.77 16.34±3.22
8u 10.95±1.95 14.75±2.15 16.76±3.30 14.75±2.57 11.92±2.16
8v 10.56±2.08 11.67±1.99 13.24±1.14 10.97±2.14 11.13±2.67
8w 16.46±1.45 14.09±2.00 15.89±1.25 14.06±2.21 17.28±4.13
Ciprofloxacin 8.04±0.15 7.89±1.54 8.54±1.76 7.29±2.67 8.11±2.12
NOTE: Minimum inhibitory concentration (MIC) was measured with suitable dilutions (5-30 µg/ well) and results were calculated 
using EZ-Fit Perrella Scientific Inc. Amherst USA software.
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highest hemolytic activity was shown by 8j (48.66%) 
which was lower than the positive control (Triton-X-100). 
Other compounds mostly showed low hemolytic activity. 
PBS was used as negative control. On the basis of the 
antibacterial and enzyme inhibition activities observed, 
we infer that the compounds synthesized, with mostly 
little toxicity, may prove to be suitable drug candidates for 
further improvements to address different targets.
Computational docking
To determine the validity of accuracy, the co-
crystallized ligands of the following enzymes were 
extracted and then re-docked into the binding pockets of 
the receptors. In all these cases, RMSD values between 
docked and co-crystallized ligands were less than 2 A°, 
indicating the reliability of the docking method, and thus, 
our protocol can be used for further studies.
Almost all the derivatives synthesized were 
computationally docked against α-glucosidase, BChE 
and LOX to explore the binding modes of all ligands 
(Figure 4). The results were very much in favor of the 
experimental work. For example, compound 8q showed 
interactions with three active site amino acid residues of 
the target protein. Amino acid Asp197 showed a strong 
hydrogen bond acceptor (polar) interaction with the 
five-member ring of the indole moiety residue, with a 
bond distance of 2.23 Å, while Trp271 showed a strong 
hydrogen bond donor interaction with the nitrogen atom 
of the oxadiazole ring, with a bond distance of 2.28 Å. 
Arg404 showed an arene cation interaction with the 
oxadiazole ring, with a bond length of 3.92 Å. The other 
residues in the nearby vicinity of the ligand were Asp73, 
Trp169, Trp417 and Ala480 (Figure 4, a).Two amino acid 
residues interacted with compound 8g; His438 interacted 
strongly with the indole moiety through a couple of arene 
cation interactions showing bond lengths of 4.62 and 4.83 
Å, while Trp82 showed arene-arene interaction with the 
oxadiazole ring, with a bond distance of 3.33 Å. Other 
residues that were in close contact with the ligand were 
Ser79, Met437, Gly116, Gln119 etc. (Figure 4, b). Strong 
metallic interactions were shown by compound 8b, with 
amino acid residues Ile857 and Asn713, via one nitrogen 
atom of the oxadiazole ring through the iron atom, giving 
bond distances of 1.81 and 2.07 Å, respectively, while 
His518 showed a hydrogen bond donor interaction with 
another nitrogen atom of the oxadiazole ring, with a 
bond length of 2.93 Å. Other residues that existed in the 
near most region of the ligand were Gln716, Ile557 and 
Leu773 (Figure 4, c).
CONCLUSION
In conclusion, this paper reports the synthesis 
of N-substituted 2-{[5-(1H-indol-3-ylmethyl)-1,3,4-
oxadiazol-2-yl]sulfanyl}acetamides (8a-w) as potential 
antibacterial agents, in view of MIC values. Compounds 
8b (9.84 ± 2.99 µM against S. typhi), 8c (9.75 ± 3.57 µM 
against S. typhi and 9.15 ± 4.12 µM against S. aureus), 
and 8l (9.96 ± 3.58 µM against S. aureus) showed 
strong antibiotic activity, which was very close to that 
of the reference standard. These results indicate that our 
synthesized molecules can be considered as suitable drug 
candidates. Moreover, the enzyme inhibition analysis was 
also supported by computational docking, and there was 
only low to moderate hemolytic activity. Compound 8q 
showed comparatively good inhibitory potential against 
α-glucosidase with an IC50 of 49.71 ± 0.19 µM, and 8g 
showed moderate inhibition of BChE, with an IC50 of 31.62 
± 0.16 µM, while all other compounds synthesized showed 
weak or no inhibition of LOX. In this regard, some of the 
compounds synthesized are potential candidates for future 
drug development studies.
TABLE IV - Hemolytic activity of N-substituted 2-{[5-(1H-indol-3-ylmethyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetamides (8a-w)
Compound % Hemolysis Compound % Hemolysis Compound % Hemolysis
8a 9.16 8i 7.69 8q 25.54
8b 5.50 8j 48.66 8r 3.03
8c 6.50 8k 3.08 8s 5.16
8d 7.40 8l 6.67 8t 2.16
8e 4.34 8m 5.16 8u 2.93
8f 5.37 8n 3.34 8v 4.50
8g 4.34 8o 4.59 8w 5.50
8h 5.50 8p 1.67
PBS 00.00 Triton-X 100.00
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FIGURE 4 - (a; 1-2) Binding modes of compound 8q against α-glucosidase, (b; 1-2) Binding modes of compound 8g against BChE, 
(c; 1-2) Binding modes of compound 8b against LOX.
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